

04-05-05
PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: **Mail**

**Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
or Fax (703) 746-4000**

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

32650 7590 01/06/2005

**WOODCOCK WASHBURN LLP
ONE LIBERTY PLACE - 46TH FLOOR
PHILADELPHIA, PA 19103**

04/06/2005 DERMANU2 00000019 10067017

01 FC:2501 700.00 OP
02 FC:1504 300.00 OP

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (703) 746-4000, on the date indicated below.

Express Mail Label No.	(Depositor's name)
EL999316379US	(Signature)
April 4, 2005	(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/067,017	02/04/2002	Michael T. Migawa	IBIS-0401	4111

TITLE OF INVENTION: NOVEL PYRANOSYL CYTOSINES: PHARMACEUTICAL FORMULATIONS AND METHODS

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	YES	\$700	\$300	\$1000	04/06/2005

EXAMINER	ART UNIT	CLASS-SUBCLASS
MCKENZIE, THOMAS C	1624	514-049000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- ☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required.

2. For printing on the patent front page, list

- (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

- 1 Isis Patent Department
2 Woodcock Washburn LLP
3 _____

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

ISIS Pharmaceuticals, Inc.

Carlsbad, California

Please check the appropriate assignee category or categories (will not be printed on the patent): ☐ Individual ☒ Corporation or other private group entity ☐ Government

4a. The following fee(s) are enclosed:

- ☒ Issue Fee
☒ Publication Fee (No small entity discount permitted)
☒ Advance Order - # of Copies 0

4b. Payment of Fee(s):

- ☒ A check in the amount of the fee(s) is enclosed.
☐ Payment by credit card. Form PTO-2038 is attached.
☒ The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 233050 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- ☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature

John A. Harrelson, Jr.

Date April 4, 2005

Typed or printed name

John A. Harrelson, Jr.

Registration No. 42,637

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



DOCKET NO.: IBIS-0401

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Migawa et al.

Confirmation No.: 4111

Application No.: 10/067,017

Group Art Unit: 1624

Filing Date: 02/04/2002

Examiner: Thomas C. McKenzie

For: Novel Pyranosyl Cytosines: Pharmaceutical Formulations and Methods

EXPRESS MAIL LABEL NO: EL999316379US

DATE OF DEPOSIT: April 4, 2005

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Applicant-Initiated Interview Summary

Date of Interview: January 4, 2005

Interview Type: ☐ Personal ☒ Telephonic ☐ Electronic Mail ☐ Video Conference ☐ Other:

Participants:

From PTO: (Include Name and Title)

1. Thomas McKenzie, Ph.D., Examiner
- 2.
- 3.

For Applicant:

1. John A. Harrelson, Jr., Attorney
2. , choose one: Applicant, Attorney, Agent
3. , choose one: Applicant, Attorney, Agent
4. , choose one: Applicant, Attorney, Agent

☐ An exhibit or demonstration was included and is described below:

The claims discussed included: Claim(s) 42 and 43

The ☐ art ☐ prior art discussed included:

An agreement ☒ was ☐ was not reached.


☐ It was agreed that the attached claims are allowable.

☐ It was agreed that the attached amendment would be entered.

☒ The interview is summarized below.

Applicants agreed to cancel claims 42 and 43, the only remaining rejected claims.

Date: April 4, 2005



John A. Harrelson, Jr.
Registration No. 42,637

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW